

PRINCE EDWARD ISLAND

Ultragenyx Canada would like to announce that ^{Pr}DOJOLVI® (triheptanoin) is eligible for public reimbursement in Prince Edward Island for patients with LC-FAOD based on the reimbursement criteria detailed below under the PEI Pharmacare Formulary.

DOJOLVI® (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at <u>https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi Final PM.pdf</u> for important information on contraindications, warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

The DOJOLVI[®] Reimbursement Criteria for the <u>PEI Pharmacare Formulary</u> Are as Follows:

For the treatment of adult and pediatric patients with an acute life-threatening long- chain fatty acid oxidation disorder (LC-FAOD) who meet the following criteria:

- Patients with a confirmed diagnosis of LC-FAOD and acute life-threatening events who require alternative therapy to conventional even-chain medium-chain triglyceride (MCT) supplementation OR
- Patients without a confirmed diagnosis of LC-FAOD presenting with acute life-threatening events consistent with LC-FAOD who require alternative therapy to conventional even-chain MCT supplementation

Claim Notes

- 1. Triheptanoin should only be prescribed by clinicians experienced in the management of LC-FAOD.
- 2. Approval: 1 year. Confirmation of continued response required.

Program Eligibility

Financial Assistance Drug Program, High Cost Drug Program, Nursing Home Drug Program, Catastrophic Drug Program

For more information on applying for DOJOLVI[®] coverage, we can arrange an appointment at your convenience, or you can visit the <u>UltraCare website</u>. You can also find the <u>UltraCare Enrolment Form</u> on the UltraCare website.

MRCP-UX007-00812 01/2024 Utrageny